Phase 1 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to provide written agreement to take part in the study and allow their personal health information to be used.
- People who are willing and able to follow the study procedures, as determined by the study doctor.
- People who are 18 years of age or older at the time of signing the consent form.
- People who have a certain level of general physical functioning, as measured by standard medical scoring tools used in cancer care (confirm with trial site).
- People who have been diagnosed with cervical cancer confirmed through tissue or cell testing, and whose treatment plan includes chemotherapy given alongside radiation therapy and brachytherapy (a type of internal radiation), except for those with known cancer spread into the rectum.
Who may not be able to join:
- People who have an active infection that requires treatment with systemic medicines (medicines that work throughout the whole body).
- People who are pregnant or currently breastfeeding, and breast milk cannot be stored for later use during the treatment period.
- People who have a known allergy to products containing hyaluronic acid.
- People who have a known inflammatory bowel condition, such as Crohn's disease or ulcerative colitis.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shivani Sud, MD, UNC Lineberger Comprehensive Cancer Center
Phone: 919-966-4432
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety based on Grade 3 or higher adverse events associated with hyaluronic acid-based rectal spacer placement; Safety based on Patient Reported Outcome Report based on The Expanded Prostate Cancer Index Composite (EPIC) Bowel Assessment; Safety based on Patient Reported Outcome Report based on Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE); Distance between uterus/cervix/proximal vagina and rectum; Gel placement procedure time; Difficulty of gel placement
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.